Shiro Kataoka

930 total citations
27 papers, 717 citations indexed

About

Shiro Kataoka is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Shiro Kataoka has authored 27 papers receiving a total of 717 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Immunology. Recurrent topics in Shiro Kataoka's work include Cell death mechanisms and regulation (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Glycosylation and Glycoproteins Research (6 papers). Shiro Kataoka is often cited by papers focused on Cell death mechanisms and regulation (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Glycosylation and Glycoproteins Research (6 papers). Shiro Kataoka collaborates with scholars based in Japan, United States and Singapore. Shiro Kataoka's co-authors include Isao Ishida, Cécile Rouleau, Beverly A. Teicher, Takashi Tsuruo, William Weber, Rebecca G. Bagley, Nakayuki Honma, Paula Boutin, Srinivas Shankara and Hiroaki Kanki and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and Blood.

In The Last Decade

Shiro Kataoka

27 papers receiving 689 citations

Peers

Countries citing papers authored by Shiro Kataoka

Since Specialization

Citations

This map shows the geographic impact of Shiro Kataoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiro Kataoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiro Kataoka more than expected).

Fields of papers citing papers by Shiro Kataoka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiro Kataoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiro Kataoka. The network helps show where Shiro Kataoka may publish in the future.

Co-authorship network of co-authors of Shiro Kataoka

This figure shows the co-authorship network connecting the top 25 collaborators of Shiro Kataoka. A scholar is included among the top collaborators of Shiro Kataoka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiro Kataoka. Shiro Kataoka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 689: Anti-tumor activity of Bifidobacterium secreting dual specific T cell redirecting antibody against EGFR/HER3-expressing cancer 2020 ·Cancer Research ·Satoshi Kobayashi, (unknown), (unknown), (unknown), Yasuyoshi Kanari, (unknown), Hikaru Nakazawa, Mitsuo Umetsu, Shiro Kataoka, Takaaki Nakamura	1
2	Abstract A23: Anti-PD-1 antibody scFv producing recombinant Bifidobacterium exerts antitumor effect in a larger fraction of the treated mice compared to full-length anti-PD-1 antibody 2018 ·Cancer Immunology Research ·(unknown), Li Wang, (unknown), (unknown), Yasuyoshi Kanari, (unknown), (unknown), Shun’ichiro Taniguchi, Shiro Kataoka	1
3	Abstract A29: Anti-CTLA-4 antibody scFv producing recombinant Bifidobacterium secretes CTLA-4 blocker specifically inside hypoxic tumor and suppresses tumor growth in syngeneic mice model 2017 ·Cancer Immunology Research ·(unknown), Shiro Kataoka, Li Wang, (unknown), (unknown), Yasuyoshi Kanari, (unknown), (unknown), Maiko Fujimori, Shun’ichiro Taniguchi	2
4	TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2 2015 ·Scientific Reports ·Taro Tamada, Daisuke Shinmi, Masahiro Ikeda, (unknown), Shiro Kataoka, Ryota Kuroki, (unknown), Kazuhiro Motoki	25
5	Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma 2008 ·Clinical Cancer Research ·Cécile Rouleau, (unknown), William Weber, Robert Smale, Leslie Kurtzberg, James T. Mascarello, Carol Berger, (unknown), Rebecca G. Bagley, Nakayuki Honma, Kazumasa Hasegawa, Isao Ishida, Shiro Kataoka, Beth L. Thurberg, (unknown), Bruce Horten, Glenn A. Miller, Beverly A. Teicher	86
6	Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248 2008 ·Molecular Cancer Therapeutics ·Rebecca G. Bagley, Cécile Rouleau, Thia St Martin, Paula Boutin, William Weber, Melanie C. Ruzek, Nakayuki Honma, Mariana Nacht, Srinivas Shankara, Shiro Kataoka, Isao Ishida, Bruce Roberts, Beverly A. Teicher	42
7	Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization 2008 ·Microvascular Research ·Rebecca G. Bagley, Nakayuki Honma, William Weber, Paula Boutin, Cécile Rouleau, Srinivas Shankara, Shiro Kataoka, Isao Ishida, Bruce Roberts, Beverly A. Teicher	78
8	Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats 2008 ·The Journal of Immunology ·(unknown), Kazumasa Hasegawa, Yusuke Sugiura, Katsuhiko Harada, Toru Miura, (unknown), Tomoyuki Tahara, (unknown), Hideaki Yoshida, Kin‐ya Kubo, Isao Ishida, Shiro Kataoka	39
9	Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor 2007 ·Nature Biotechnology ·Masayuki Kai, Kazuhiro Motoki, Hideaki Yoshida, (unknown), (unknown), (unknown), (unknown), (unknown), Munetake Shimabe, (unknown), Tetsuya Hagiwara, Atsushi Matsumoto, Hiroshi Miyazaki, Shiro Kataoka	23
10	Fully human antibody exhibits pan‐human leukocyte antigen‐DR recognition and high in vitro/vivo efficacy against human leukocyte antigen‐DR‐positive lymphomas 2007 ·Cancer Science ·(unknown), Kazumasa Hasegawa, Yusuke Sugiura, Tomoyuki Tahara, Isao Ishida, Shiro Kataoka	5
11	Domain Subclass Conversion Improved Activity of Anti-Mpl Agonist Antibodies in the Form of Whole IgG. 2006 ·Blood ·Masayuki Kai, Kazuhiro Motoki, Hideaki Yoshida, (unknown), (unknown), (unknown), (unknown), (unknown), Munetake Shimabe, Hiroshi Miyazaki, Shiro Kataoka	10
12	Distinct function of monoclonal antibody to TRAIL‐R2 as potentiator or inhibitor of the ligand TRAIL‐induced apoptosis 2005 ·FEBS Letters ·(unknown), (unknown), Kazuhiro Motoki, Shiro Kataoka	2
13	Direct interaction of insulin-like growth factor-1 receptor with leukemia-associated RhoGEF 2001 ·The Journal of Cell Biology ·Shinichiro Taya, Naoyuki Inagaki, (unknown), Hiroshi Makino, Akihiro Iwamatsu, Itaru Urakawa, Kenji Nagao, Shiro Kataoka, Kozo Kaibuchi	92
14	Structural Modification of Fas C-Terminal Tripeptide and Its Effects on the Inhibitory Activity of Fas/FAP-1 Binding 1999 ·Journal of Medicinal Chemistry ·Eiji Sawa, M Takahashi, Masaru Kamishohara, (unknown), Kaname Kimura, Midori A. Arai, (unknown), Shiro Kataoka, Tsuyoshi Nishitoba	6
15	Differences in apoptosis induced by anticancer drugs in sublines (SKG-3a, SKG-3b) from a human uterine cervical epidermoid carcinoma. 1999 ·PubMed ·M Takahashi, Shiro Kataoka, Eiichi Kobayashi, Yasuhiro Udagawa, Daisuke Aoki, Shinji Oie, (unknown), Shiro Nozawa	1
16	Apoptosis resistance in tumor cells 1998 ·Cytotechnology ·Tetsuo Mashima, Hiroyuki Seimiya, Zhihong Chen, Shiro Kataoka, Takashi Tsuruo	6
17	The Molecular Interaction of Fas and FAP-1 1997 ·Journal of Biological Chemistry ·Junn Yanagisawa, M Takahashi, Hiroaki Kanki, (unknown), (unknown), Eiji Sawa, Tsuyoshi Nishitoba, Masaru Kamishohara, Eiichi Kobayashi, Shiro Kataoka, Takaaki Sato	117
18	Apoptosis 1996 ·The Oncologist ·Shiro Kataoka, Takashi Tsuruo	12
19	Resistance to Antitumor Agent-Induced Apoptosis in a Mutant of Human Myeloid Leukemia U937 Cells 1994 ·Experimental Cell Research ·Shiro Kataoka, Mikihiko Naito, Akihiro Tomida, Takashi Tsuruo	37
20	Control of Apoptosis and Growth of Malignant T Lymphoma Cells by Lymph Node Stromal Cells 1993 ·Experimental Cell Research ·Shiro Kataoka, Mikihiko Naito, Naoya Fujita, (unknown), Shigetaka Ishii, Takao Yamori, Motowo Nakajima, Takashi Tsuruo	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact